AHCC (Active Hexose Correlated Compound) is a standardized extract derived from the mycelia of shiitake mushrooms and is widely marketed as a supplement to support immune function. There is some scientific interest in its potential benefits for the hepatic (liver) system, particularly in the context of liver protection and as an adjunct in the treatment of certain liver diseases.

Preclinical studies (primarily in animal models) have shown that AHCC may exert hepatoprotective effects, potentially reducing liver injury induced by toxins or viruses. For example, AHCC has demonstrated the ability to decrease markers of liver damage (such as ALT and AST) and improve antioxidant status in rodent models of chemically induced liver injury. There is also limited evidence suggesting that AHCC may have beneficial immunomodulatory effects that could support the liver’s response to viral infections, such as hepatitis B and C, though human data is lacking or preliminary.

However, robust, high-quality clinical trials in humans specifically examining AHCC’s effects on liver health are limited. Most available evidence is either from animal studies or small pilot human trials, often with methodological limitations. Thus, while there is a scientific basis for ongoing research, the current level of evidence supporting AHCC for hepatic support in humans is modest at best, justifying a rating of 2 out of 5.